Table 1 Clinico-pathologic variables and immunoreactivity status of PD-1 and PD-L1 in 99 NPC patients.
From: PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load
Variables | n | PD-1 Positive | P value1 | PD-L1 High2 | P value1 | |
|---|---|---|---|---|---|---|
Gender | Male | 68 | 30 (44. 1%) | 0.923 | 44 (64.7%) | 0.349 |
| Ā | Female | 31 | 14 (45.2%) | Ā | 17 (54.8%) | Ā |
Age (years) | <50 | 60 | 27 (45.0%) | 0.890 | 35 (58.3%) | 0.405 |
| Ā | ā„50 | 39 | 17 (43.6%) | Ā | 26 (66.7%) | Ā |
Smoking status | Smoker or ex-smoker | 34 | 15 (44.1%) | 0.962 | 20 (58.8%) | 0.679 |
| Ā | Non-smoker | 65 | 29 (44.6%) | Ā | 41 (63.1%) | Ā |
Family history | Yes | 25 | 14 (56.0%) | 0.179 | 13 (52.0%) | 0.253 |
| Ā | No | 74 | 30 (40.5%) | Ā | 48 (64.9%) | Ā |
Tumour size | rT1-3 | 71 | 33 (46.5%) | 0.517 | 43 (60.6%) | 0.732 |
| Ā | rT4 | 28 | 11 (39.3%) | Ā | 18 (64.3%) | Ā |
Nodal status | N0-1 | 54 | 22 (40.7%) | 0.417 | 33 (61.1%) | 0.910 |
| Ā | N2-3 | 45 | 22 (48.9%) | Ā | 28 (62.2%) | Ā |
Clinical stage3 | I-III | 65 | 29 (44.6%) | 0.962 | 38 (58.5%) | 0.372 |
| Ā | IV | 34 | 15 (44.1%) | Ā | 23 (67.6%) | Ā |
GTVnx (mm3)2 | <29.6 | 45 | 22 (48.9%) | 0.417 | 28 (62.2%) | 0.910 |
| Ā | ā„29.6 | 54 | 22 (40.7%) | Ā | 33 (61.1%) | Ā |
EBV-DNA load | Undetectable | 22 | 10 (45.5%) | 0.914 | 12 (54.5%) | 0.439 |
| Ā | Detectable | 77 | 34 (44.2%) | Ā | 49 (63.6%) | Ā |
PD-1 positivity | Negative | 55 | Ā | Ā | 31 (56.4%) | 0.230 |
| Ā | Positive | 44 | Ā | Ā | 30 (68.2%) | Ā |
